William Greene

Archus Orthopedics, Inc. develops implantable medical devices for spine disorders resulting from degenerative changes in the facet joints. Its products include Total Facet Arthroplasty System and Archus-UWABL spine simulator. Archus Orthopedics was founded by Scott J. Wolf in July 2001 and is headquartered in Redmond, WA.

QuatRx Pharmaceuticals Co. manufactures and develops therapeutic compounds. Its clinical products, ospemifene and fispemifene, treat hormone deficiencies that result from aging in women and men. The firm's preclinical program is designed to address sex steroid dependent diseases through inhibition of 17beta- hydroxysteroid dehydrogenase (HSD) enzymes. The company was founded by Robert Zerbe, Christopher Nicholas, and Stuart Dombey on November 20 2000 and is headquartered in Ann Arbor, MI.

Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria.

Verus Pharmaceuticals, Inc. was provided pediatric-oriented pharmaceutical products. The company was founded by David A. Socks, James Carroll Blair, Robert W. Keith, Cam L. Garner and David F. Hale in 2002 and was headquartered in San Diego, CA.

Viral Logic Systems Technology Corp. provides pharmaceutical products and services. It develops treatments for autoimmune, inflammatory diseases and disorders. The company was founded by Steven R. Wiley and Craig A. Smith in 2004 and headquartered in Seattle, WA.

Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA.

Genentech Ventures (Genentech Ventures) is a venture capital firm founded in 1900. The firm is headquartered in South San Francisco, CA.

EndoGastric Solutions, Inc. develops natural orifice surgical products and procedures to advance the treatment of gastrointestinal diseases. The firm offers EsophyX device and StomaphyX device. The company was founded by Stefan J. M. Kraemer, Clifton A. Alferness, Scott Jordan Wolf, James W. Fitzsimmons and John M. Adams in 2003 and is headquartered in Redmond City, WA.

SAI Life Sciences Ltd. manufactures, develops, and discovers pharmaceutical drugs. The company was founded in 1999 and is headquartered in Hyderabad, India.

American College of Physicians, Inc. operates as a medical-specialty organization. It is a national organization of internists and physician specialists who apply scientific knowledge and clinical expertise to the diagnosis, treatment, and care of adults from health to complex illness. Its members include internists, internal medicine subspecialists, medical students, residents, and fellows. The company was founded in 1915 and is headquartered Philadelphia, PA.

Pear Therapeutics (US), Inc. develops and provides a platform that combines pharmaceutical preparations with scientifically validated software applications. It offers eFormulation, pharmaceutical-software combination products. The firm combines digital therapies with supplements, medical foods and pharmaceuticals to create more effective treatment solutions. The company was founded in 2013 by Corey M. McCann, Stephen Kennedy Smith and William Greene and is headquartered in Boston. MA.

Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA.

Fountain Therapeutics, Inc. develops treatment for aging-associated diseases. The company is headquartered in San Francisco, CA.